Here's which life science companies — in Houston and beyond — are ones to watch. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Last week, the Rice Alliance for Technology and Entrepreneurship gathered over 1,000 life science experts and attendees virtually for thought leadership as well as 40 company presentations.

The three-day 2020 Virtual Texas Life Science Forum was made possible through a partnership with BioHouston and support from Texas Medical Center and Insperity. At the close of the summit, several companies were recognized with awards.

Houston-based Starling Medical won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The digital health device company is revolutionizing severe bladder dysfunction management with artificial intelligence.

Every year at the forum, the Rice Alliance names its 10 most promising companies working on developing innovative solutions in medical devices, digital health, diagnostics, pharmaceuticals, and therapeutics. This year, Brad Burke, managing director of the Rice Alliance, says they had more applications to present than ever before. Additionally, the presenting companies — about half of which are Houston-based — have already raised more than $275 million in funding.

The 2020 most-promising life science companies, which were chosen by investors and presented by the Greater Houston Partnership, were:

Droice Labs

Image via droicelabs.com

New York-based Droice Labs, is an artificial intelligence and big data company matches patients to therapies and delivers personalized medicine at scale while reducing costs.

"Our cutting-edge technology seamlessly integrates into clinical workflows, and we continue to evolve unique and powerful applications for our clients and the patients they serve," reads the company's website.

SFA Therapeutics

Image via sfatherapeutics.com

Based in Jenkintown, Pennsylvania, SFA Therapeutics is developing oral drugs for treating conditions of chronic inflammation that have the potential to change the practice of medicine. The company has treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.

Hummingbird Bioscience

Photo via jlabs.jnjinnovation.com

Hummingbird Bioscience, based in Houston's JLABS @ TMC, is tackling challenging targets that play a key role in disease yet have not been effectively drugged. The company has worked on 12 therapies in various stages of development, four of which have the potential to revolutionize their fields.

"At Hummingbird, we believe that modern approaches to systems biology and data science can overcome the challenges of classical methods of therapeutics discovery, and profoundly improve the way we deliver new transformative medicines," reads the company website.

CaseCTRL

Image via casectrl.com

Houston-based CaseCTRL is empowering surgeons with a management platform with software-as-a-service technology that uses AI and logistics to lower operational costs and simplify surgical planning.

"The surgical scheduling process is frustratingly stuck in the past: siloed, paper-based, and too dependent on single schedulers," reads the website. "Surgeons are stressed and overworked. They need a better way to communicate their complex surgical plans, timelines and resource needs."

Perimeter Medical

Image via perimetermed.com

Perimeter Medical, based in Dallas, is driven to transform cancer surgery with advanced, real-time, ultra high-resolution imaging tools including AI to address areas of unmet medical need.

"Perimeter is dedicated to providing solutions that drive better patient care and lower healthcare costs by providing critical information, during clinical procedures," reads the website.

Studio Bahria

Image via studiobahia.org

San Antonio-based Studio Bahia, is developing an accessible model for therapy in addressing mental health crises from the pandemic through virtual reality.

"We are in production of our first two therapies for release in the 4th quarter of 2020. Studio Bahia clients include corporate, retail, and institutional partners who purchase our headsets for $25 in providing mental health therapies and wellness tools to employees, executives, and patients," reads the company's website.

Tvardi Therapeutics

Photo via Getty Images

Tvardi Therapeutics, based in Houston, is a clinical-stage biopharmaceutical company focused on the development of a new class of breakthrough medicines for diverse cancers and chronic inflammatory and fibrotic diseases.

"Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways," reads the website.

Koda Health

Image via kodahealthcare.com

Koda Health, Houston, uses AI to help guide difficult conversations in health care, starting with end-of-life care planning.

"You're entitled to protect the healthcare decisions that matter most to you and your family," the company's website promises. "Koda creates Care Plans to ensure that you get the medical care you want."

Immuno Genesis

Photo via Getty Images

Houston-based ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically "cold" cancers such as prostate, colorectal, and pancreatic.

"Compared to existing immunotherapy drugs, we believe this antibody will both provide more consistent benefit for patients with immune-infiltrated tumors, and, for the first time, will also benefit patients with immune 'cold' cancers," says founder Dr. Michael A. Curran in a press release announcing the company's grant from the Cancer Prevention and Research Institute of Texas.

Ictero Medical

Image via Getty Images

Ictero Medical, based in Houston, is developing the first minimally invasive cryoablation solution to treat patients with gallstone disease. Ictero Medical has created a minimally invasive treatment, called The CholeSafe System, that uses cryoablation to defunctionize the gallbladder without having to remove it.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson receives $10M gift to launch pancreatic cancer program

med funding

The University of Texas MD Anderson Cancer Center will be getting a significant boost in the fight against pancreatic cancer thanks to a recent gift from longtime supporters Zelma and William Reid. The medical system announced this month that a $10 million donation would help it establish a new Pancreatic Cancer High-Risk Interception Program.

“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

Pancreatic cancer is one of the most deadly types of cancer. Despite being relatively rare, it ranks third in total deaths from cancer in the United States. Less than 10 percent of patients diagnosed with pancreatic cancer are still alive five years later.

Dr. Florencia McAllister, William Reid, Dr. Michael P. Kim, Zelma Reid, Dr. Manoop S. Bhutani, and Dr. Matthew H.G. Katz. Photo courtesy MD Anderson

The problem is often detection. The pancreas is located deep in the upper abdomen among many other organs, which can make spotting tumors difficult. Some blood tests can indicate pancreatic cancer, but it is usually not diagnosed until it spreads.

The new Pancreatic Cancer High-Risk Interception Program hopes to assemble new diagnostic techniques and patient screening tools to increase early detection. MD Anderson’s Dr. Michael P. Kim, associate professor of surgical oncology; Dr. Manoop S. Bhutani, professor of gastroenterology and hepatology; and Dr. Florencia McAllister, professor of gastrointestinal medical oncology and genetics, will lead the new program.

The team will rely on advanced imaging, molecular diagnostics, AI-driven assessment, and DNA testing to both create an at-risk patient population profile and hopefully help detect the cancer in its earliest stages. For instance, some of these tools will be able to monitor pancreatic cysts without invasive surgery.

“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim added in the release. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

Axiom Space inks partnership to grow semiconductor crystals in orbit

space deal

Down in Webster, Texas, and high above the Earth, Axiom Space and Kansas-based Nitride Global Inc. will grow the next generation of semiconductor crystals in microgravity thanks to a new memorandum of understanding (MOU) signed earlier this month.

“Signing this MOU with Nitride Global reflects the growing commercial interest in producing advanced semiconductor materials in space,” Lucie Low, chief science officer for Axiom Space, said in a news release. “Their leadership in aluminium nitride (AlN) crystal growth and advanced packaging technologies, combined with Axiom Space’s capabilities in orbital infrastructure and mission integration, position us to demonstrate real commercial value in low-Earth orbit (LEO).”

This latest partnership builds on existing collaboration between Axiom and NitrideGlobal and NASA Ames Research Center.

Aluminium nitride crystals are part of the cutting-edge generation of semiconductors essential to emerging high-voltage transistors and also used in various medical technologies. Because of their high thermal stability, they can be used in a variety of environments and applications that have revolutionized everything from electric cars to the grids the cars run on.

However, the crystals are challenging to grow on Earth and face defects and size limitations due to gravity. Growing them in space can enhance their performance, according to NitrideGlobal. Microgravity allows them to grow more uniformly and with fewer defects, potentially resulting in larger, purer and more reliable crystals.

That’s where Axiom Space comes in. The company is developing Axiom Station, a successor to the International Space Station, where new research and manufacturing can be carried out.

“This MOU marks a pivotal milestone in our close partnership with Axiom Space that started as part of the NASA Small Business Innovation Research (SBIR) for AlN growth in space and is now expanding to usher the development of an innovation ecosystem,” Mahyar Khosravi, CEO of Nitride Global Inc., added in the release. “With Axiom Space’s leadership in the in-space manufacturing sector, this partnership will aim to deliver a platform for commercially viable manufacturing of [ultrawide bandgap materials] that will enable the next generation of semiconductor & microelectronics for terrestrial and planetary exploration uses.”

Houston's IAH lands on list of 15 most expensive U.S. airports

Travel Woes

Hold on to those carry-on bags: George Bush Intercontinental Airport is checking in as one of the 15 most expensive airports in the U.S., a new study has revealed.

The analysis from digital commerce and marketing platform ConsumerVoice.org compared the average domestic flight costs at the 50 largest U.S. airports, ranking them from highest to lowest. Flight price data was sourced from the U.S. Department of Transportation’s Bureau of Transportation Statistics (BTS) during the first and second quarters of 2026 and compared with the same period in 2025.

Washington Dulles International Airport in Virginia tops the list as the priciest major airport in the U.S, with domestic flights at IAD costing $534.34 on average. Charlotte Douglas International Airport in North Carolina comes in second place with an average fare cost of $527.79.

IAH lands at No. 13 nationwide, and it's the second most expensive in Texas, the findings show. The typical domestic flight from IAH costs $482.02, and they aren't getting any cheaper. Flights out of IAH are nine percent more expensive than they were a year ago, the report found. The average domestic flight cost $37.80 less in 2025.

Houstonians not only need to be prepared to spend a little extra money when booking their tickets; they'll also need to pack their patience, as IAH also ranks among the worst airports for flight delays and cancellations.

Travelers on a budget can save more on flights out of William P. Hobby Airport, if they're willing to make the drive. Travelers can save about 13 percent on their flights by flying through HOU instead of IAH, but there are other costs to take into consideration.

"Ground transportation, gas, and parking can eat into the difference, so factor these in when choosing the most economical departure airport," the report said.

HOU ranked as the No. 31 most expensive airport on the list with domestic flights coming in at $417.78 on average. Average fares at HOU are also nine percent more expensive than they were last year.

The top 10 priciest major airports in the U.S. are:

  • No. 1 – Washington Dulles International Airport
  • No. 2 – Charlotte Douglas International Airport
  • No. 3 – Detroit metro Wayne County Airport
  • No. 4 – Salt Lake City International
  • No. 5 – Minneapolis-St. Paul International
  • No. 6 – San Francisco International
  • No. 7 – John F. Kennedy International
  • No. 8 – Newark Liberty International
  • No. 9 – Dallas/Fort Worth International
  • No. 10 – Hartsfield-Jackson Atlanta International
---

This article originally appeared on CultureMap.com.